Author information:
(1)Division of Hematology/Oncology, Department of Internal Medicine, Mayo 
Clinic, Phoenix, AZ 85054, USA.
(2)Division of Cancer Sciences, University of Manchester & Department of Medical 
Oncology, The Christie Hospital NHS Foundation Trust, The University of 
Manchester, Manchester, UK.
(3)Department of Oncology, University of Leuven, Leuven, Belgium.
(4)Department of Oncology and Hematology, Humanitas Clinical and Research 
Center-IRCCS, Rozzano, Milan, Italy.
(5)Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 
Milan, Italy.
(6)Department of Medical Oncology, Kyorin University, Tokyo, Japan.
(7)Department of Cancer Survey and Gastrointestinal Oncology, Osaka 
International Cancer Institute, Osaka, Japan.
(8)Department of Medicine, University of Verona, Verona, Italy.
(9)Medical Oncology Department, Vall d'Hebron University Hospital & Vall 
d'Hebron Institute of Oncology, Barcelona, Spain.
(10)Research Department of Oncology, UCL Cancer Institute, University College 
London, London, UK.
(11)Department of Medical Oncology, Hammersmith Hospital, Imperial College 
Health Care Trust, London, UK.
(12)Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 
NY, USA.
(13)Department of Medicine, Weill Medical College, Cornell University, New York, 
NY, USA.
(14)Incyte Corporation, Wilmington, DE, USA.
(15)Incyte Biosciences International Sàrl, Morges, Switzerland.
(16)Department of Gastroenterology, Hepatology and Endocrinology, Hannover 
Medical School, Hannover, Germany.